Compare Biogen Inc (BIIB) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Uber Technologies Inc — how do they compare? Biogen Inc trades at $190.68 (market cap $28.34B), while Uber Technologies Inc trades at $72.82 (market cap $146.73B). The key difference: Uber Technologies Inc is far larger — about 5.2× Biogen Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | UBER | |
|---|---|---|
Market Cap | $28.34B | $146.73B |
Sector | Health | Industrials |
52-Week High | $216.63 | $100.10 |
52-Week Low | $122.68 | $68.61 |
Enterprise Value | $30.62B | $153.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Uber Technologies (UBER) trades at $74.26, down 0.38% on the day, with strong analyst consensus of 49 buys and 0 sells. The stock shows bullish technical signals with moving averages supporting upward momentum. Fundamentally, Uber demonstrates robust revenue growth from $31.9B in 2022 to $52.0B in 2025, though net income margin has moderated from 22.41% to 19.32%. Recent developments include strategic moves into autonomous vehicles with partnerships in Spain and Germany.
Uber presents a compelling growth story with expanding profitability and dominant market position. The 36% upside to consensus price target of $108.92 suggests significant potential. Key risks include execution challenges in autonomous vehicle rollout, competitive pressures in key markets like India, and potential margin compression. Operating cash flow strength at $10.1B supports continued investment in growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
